Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 24

Sort by

Sort Order Select

Journal Articles

Impact of Imaging FDG-PET/CT Minimal Residual Disease Assessment on Outcomes and Matching with Bone Marrow Techniques in Newly Diagnosed Transplant Eligible Multiple Myeloma (MM) Patients: Results of the Phase II Randomized Forte Trial

Blood (2020) 136 (Supplement 1): 27–28.

https://doi.org/10.1182/blood-2020-137412

Published: 2020

Journal Articles

The Optimal Timing of Interim 18F-FDG PET in Diffuse Large B-Cell Lymphoma: An Individual Patient Data Meta-Analysis By the Petra Consortium

Blood (2019) 134 (Supplement_1): 487.

https://doi.org/10.1182/blood-2019-122298

Published: 2019

Journal Articles

MRD Evaluation By PET/CT According to Deauville Criteria Combined with Multiparameter Flow Cytometry in Newly Diagnosed Transplant Eligible Multiple Myeloma (MM) Patients Enrolled in the Phase II Randomized Forte Trial

Blood (2019) 134 (Supplement_1): 4321.

https://doi.org/10.1182/blood-2019-125134

Published: 2019

Journal Articles

Standardization of 18F-FDG PET/CT According to Deauville Criteria for MRD Evaluation in Newly Diagnosed Transplant Eligible Multiple Myeloma Patients: Joined Analysis of Two Prospective Randomized Phase III Trials

Blood (2018) 132 (Supplement 1): 257.

https://doi.org/10.1182/blood-2018-99-111321

Published: 2018

Journal Articles

PET/CT Guided Biopsy for the Diagnosis of Lymphoma

Alessandro Broccoli, Cristina Nanni, Alberta Cappelli, Francesco Bacci, MD, Alessandro Gasbarrini, Lucia Zanoni, Stefano Brocchi, Sebastiano Spagnolo, Carlo Piovani, Lisa Argnani, Stefano Boriani, Elena Sabattini, Rita Golfieri, Stefano Fanti, Pier Luigi Zinzani, MD

Blood (2017) 130 (Supplement 1): 2857.

https://doi.org/10.1182/blood.V130.Suppl_1.2857.2857

Published: 2017

Journal Articles

Prospective Evaluation of 18F-FDG PET/CT As Predictor of Prognosis in Newly Diagnosed Transplant Eligible Multiple Myeloma (MM) Patients: Results from the Imaging Sus-Study of the EMN02/HO95 MM Randomized Phase III Trial

Blood (2016) 128 (22): 992.

https://doi.org/10.1182/blood.V128.22.992.992

Published: 2016

Journal Articles

18F-Fluorothymidine Positron Emission Tomography in Patients with Suspect Lymphoma Relapse

Alessandro Broccoli, MD, Lucia Zanoni, Cristina Nanni, Giancarlo Montini, Vittorio Stefoni, Cinzia Pellegrini, Letizia Gandolfi, Cristina Fonti, Filippo Lodi, Michele Cavo, MD, Stefano Fanti, Pier Luigi Zinzani, MD PhD

Blood (2015) 126 (23): 5009.

https://doi.org/10.1182/blood.V126.23.5009.5009

Published: 2015

Journal Articles

The Presence of FDG PET/CT Focal, Not Osteolytic, Lesion(s) Identifies a Sub-Group of Patients with Smoldering Multiple Myeloma with High-Risk of Progression into Symptomatic Disease

Elena Zamagni, MD, Cristina Nanni, MD, Francesca Gay, MD, Annalisa Pezzi, Statistician, Marilena Bellò, MD, Ilaria Rambaldi, MD, Paola Tacchetti, MD, Annamaria Brioli, MD, Lucia Pantani, MD, Valeria Magarotto, MD, Beatrice Anna Zannetti, MD, Massimo Menga, MD, Giulia Marzocchi, PhD, Carolina Terragna, PhD, Katia Mancuso, MD, Antonio Palumbo, MD, Stefano Fanti, MD, Michele Cavo, MD

Blood (2014) 124 (21): 3371.

https://doi.org/10.1182/blood.V124.21.3371.3371

Published: 2014

Journal Articles

PET/CT Is a Useful Tool For Both Refining The Definition Of Complete Response (CR) In Multiple Myeloma (MM) and Detecting Otherwise Unrevealed Progression During The Follow-Up Of The Disease: A Single Centre Experience On 282 Patients

Elena Zamagni, MD, Cristina Nanni, MD, Annalisa Pezzi, Statistics, Katia Mancuso, Paola Tacchetti, MD, Lucia Pantani, MD, Beatrice Anna Zannetti, MD, Annamaria Brioli, MD, Serena Rocchi, MD, Giulia Marzocchi, PhD, Nicoletta Testoni, BS, Carolina Terragna, PhD, Giovanni Martinelli, MD, Stefano Fanti, MD, Michele Cavo, MD

Blood (2013) 122 (21): 1936.

https://doi.org/10.1182/blood.V122.21.1936.1936

Published: 2013

Journal Articles

Sequential R-CHOP and R-FM Chemotherapy Followed By Autologous Stem Cell Transplantation Results In High Rates Of Long Term Remission In Advanced Follicular Lymphoma

Enrico Derenzini, MD, Vittorio Stefoni, MD, Beatrice Casadei, MD, Cinzia Pellegrini, MD, Alessandro Broccoli, MD, Stefano Fanti, MD, Letizia Gandolfi, MD, Giulia Stefani, MD, Lisa Argnani, PhD, Pier Luigi Zinzani, MD

Blood (2013) 122 (21): 5543.

https://doi.org/10.1182/blood.V122.21.5543.5543

Published: 2013

Journal Articles

Collection of Hematopoietic Stem Cells After Previous Exposure to Ittrium-90 Ibritumumab Tiuxetan (Zevalin) Is Feasible and Does Not Impair Autologous Stem Cell Transplantation Outcome in Follicular Lymphoma.

Enrico Derenzini, MD, Cinzia Pellegrini, MD, Roberto Maglie, Vittorio Stefoni, MD, Alessandro Broccoli, MD, Letizia Gandolfi, MD, Beatrice Casadei, MD, Federica Quirini, MD, Lisa Argnani, PhD, Stefano Fanti, MD, Maria Rosa Motta, PhD, Michele Baccarani, MD, Pier Luigi Zinzani, MD

Blood (2012) 120 (21): 3019.

https://doi.org/10.1182/blood.V120.21.3019.3019

Published: 2012

Journal Articles

Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation

Elena Zamagni, Francesca Patriarca, Cristina Nanni, Beatrice Zannetti, Emanuela Englaro, Annalisa Pezzi, Paola Tacchetti, Silvia Buttignol, Giulia Perrone, Annamaria Brioli, Lucia Pantani, Carolina Terragna, Francesca Carobolante, Michele Baccarani, Renato Fanin, Stefano Fanti, Michele Cavo

Blood (2011) 118 (23): 5989–5995.

https://doi.org/10.1182/blood-2011-06-361386

Published: 2011

Journal Articles

Conventionally-Defined and PET/CT-Defined Complete Response (CR) to Novel Agent-Based Induction Therapy and Autologous Stem-Cell Transplantation (ASCT) In Multiple Myeloma (MM): A Prospective Study of Clinical and Prognostic Implications

Elena Zamagni, MD, Cristina Nanni, MD, Francesca Patriarca, MD, Annalisa Pezzi, Statistician, Beatrice Anna Zannetti, MD, Paola Tacchetti, MD, Emanuela Englaro, MD, Giulia Perrone, MD, Silvia Buttignol, MD, Annamaria Brioli, MD, Lucia Pantani, MD, Francesca Carobolante, MD, Michele Baccarani, MD, Stefano Fanti, MD, Michele Cavo, MD

Blood (2011) 118 (21): 826.

https://doi.org/10.1182/blood.V118.21.826.826

Published: 2011

Journal Articles

Early Interim 18 f-FDG PET In Hodgkin's Lymphoma: Evaluation on 304 Patients

Blood (2010) 116 (21): 3879.

https://doi.org/10.1182/blood.V116.21.3879.3879

Published: 2010

Journal Articles

Prognostic Relevance of 18F-FDG PET/CT In Newly Diagnosed Multiple Myeloma Patients Treated with up-Front Autologous Transplantation: A Prospective Study

Elena Zamagni, Cristina Nanni, Francesca Patriarca, Paola Tacchetti, Emanuela Englaro, Giulia Perrone, Silvia Buttignol, Annamaria Brioli, Lucia Pantani, Beatrice Anna Zannetti, Francesca Caroborante, Michele Baccarani, Stefano Fanti, Michele Cavo

Blood (2010) 116 (21): 369.

https://doi.org/10.1182/blood.V116.21.369.369

Published: 2010

Journal Articles

Predictive role of Early Interim FDG-PET in Hodgkin Lymphoma.

Vittorio Stefoni, Alessandro Broccoli, Lapo Alinari, Valentina Ambrosini, Enrico Derenzini, Stefano Fanti, Mariapaola Fina, Letizia Gandolfi, Enrica Marchi, Cinzia Pellegrini, Federica Quirini, Pier Luigi Zinzani, Michele Baccarani

Blood (2009) 114 (22): 1659.

https://doi.org/10.1182/blood.V114.22.1659.1659

Published: 2009

Journal Articles

A Phase II Trial of R-FM (Rituximab, Fludarabine and Mitoxantrone) Chemotherapy Followed by Yttrium 90 ( 90 Y) Ibritumomab Tiuxetan ( 90 Y-IT) for Untreated Follicular Lymphoma (FL) Patients.

Pier Luigi Zinzani, Monica Tani, Alessandro Broccoli, Enrico Derenzini, Alessandro Pulsoni, Amalia De Renzo, Stefano Fanti, Mariapaola Fina, Letizia Gandolfi, Cinzia Pellegrini, Vittorio Stefoni, Michele Baccarani

Blood (2009) 114 (22): 3743.

https://doi.org/10.1182/blood.V114.22.3743.3743

Published: 2009

Journal Articles

A Phase II Trial of Rituximab-CHOP Chemotherapy Followed by Yttrium 90 ( 90 Y) Ibritumomab Tiuxetan ( 90 Y-IT) for Previously Untreated Elderly Diffuse Large B-Cell Lymphoma (DLBCL) Patients.

Pier Luigi Zinzani, Mariapaola Fina, Monica Tani, Vittorio Stefoni, Letizia Gandolfi, Alessandro Broccoli, Cinzia Pellegrini, Enrico Derenzini, Giuseppe Rossi, MD, Emanuele Angelucci, Gianluca Gaidano, Maria Concetta Petti, Maurizio Martelli, Umberto Vitolo, Stefano Fanti, Michele Baccarani

Blood (2009) 114 (22): 2720.

https://doi.org/10.1182/blood.V114.22.2720.2720

Published: 2009

Journal Articles

ITF2357, a Novel Histone-Deacetylase Inhibitor, Is Effective against Peripheral T-Cell Lymphomas in Vivo

Pier Paolo Piccaluga, Maura Rossi, Aurora Esposito, Pier Luigi Tazzari, Francesca Ricci, Giordano Nicoletti, Lorena Landuzzi, Stefano Fanti, Valentina Ambrosini, Flavio Leoni, Paolo Mascagni, Anna Gazzola, Pier Luigi Lollini, Pier Luigi Zinzani, Stefano A. Pileri

Blood (2008) 112 (11): 4981.

https://doi.org/10.1182/blood.V112.11.4981.4981

Published: 2008

Journal Articles

FDG-PET in the Serial Assessment of Patients with Lymphoma in Complete Remission.

Pier Luigi Zinzani, MD, PhD, Vittorio Stefoni, MD, Valentina Ambrosini, MD, Enrico Derenzini, MD, Gerardo Musuraca, MD, Enrica Marchi, MD, Lapo Alinari, MD, Mariapaola Fina, MD, Monica Tani, MD, Cinzia Pellegrini, MD, Stefano Fanti, MD, Michele Baccarani, MD

Blood (2007) 110 (11): 216.

https://doi.org/10.1182/blood.V110.11.216.216

Published: 2007

NARROW

Impact of Imaging FDG-PET/CT Minimal Residual Disease Assessment on Outcomes and Matching with Bone Marrow Techniques in Newly Diagnosed Transplant Eligible Multiple Myeloma (MM) Patients: Results of the Phase II Randomized Forte Trial

The Optimal Timing of Interim 18F-FDG PET in Diffuse Large B-Cell Lymphoma: An Individual Patient Data Meta-Analysis By the Petra Consortium

MRD Evaluation By PET/CT According to Deauville Criteria Combined with Multiparameter Flow Cytometry in Newly Diagnosed Transplant Eligible Multiple Myeloma (MM) Patients Enrolled in the Phase II Randomized Forte Trial

Standardization of 18F-FDG PET/CT According to Deauville Criteria for MRD Evaluation in Newly Diagnosed Transplant Eligible Multiple Myeloma Patients: Joined Analysis of Two Prospective Randomized Phase III Trials

PET/CT Guided Biopsy for the Diagnosis of Lymphoma

Prospective Evaluation of 18F-FDG PET/CT As Predictor of Prognosis in Newly Diagnosed Transplant Eligible Multiple Myeloma (MM) Patients: Results from the Imaging Sus-Study of the EMN02/HO95 MM Randomized Phase III Trial

18F-Fluorothymidine Positron Emission Tomography in Patients with Suspect Lymphoma Relapse

The Presence of FDG PET/CT Focal, Not Osteolytic, Lesion(s) Identifies a Sub-Group of Patients with Smoldering Multiple Myeloma with High-Risk of Progression into Symptomatic Disease

PET/CT Is a Useful Tool For Both Refining The Definition Of Complete Response (CR) In Multiple Myeloma (MM) and Detecting Otherwise Unrevealed Progression During The Follow-Up Of The Disease: A Single Centre Experience On 282 Patients

Sequential R-CHOP and R-FM Chemotherapy Followed By Autologous Stem Cell Transplantation Results In High Rates Of Long Term Remission In Advanced Follicular Lymphoma

Collection of Hematopoietic Stem Cells After Previous Exposure to Ittrium-90 Ibritumumab Tiuxetan (Zevalin) Is Feasible and Does Not Impair Autologous Stem Cell Transplantation Outcome in Follicular Lymphoma.

Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation

Conventionally-Defined and PET/CT-Defined Complete Response (CR) to Novel Agent-Based Induction Therapy and Autologous Stem-Cell Transplantation (ASCT) In Multiple Myeloma (MM): A Prospective Study of Clinical and Prognostic Implications

Early Interim 18 f-FDG PET In Hodgkin's Lymphoma: Evaluation on 304 Patients

Prognostic Relevance of 18F-FDG PET/CT In Newly Diagnosed Multiple Myeloma Patients Treated with up-Front Autologous Transplantation: A Prospective Study

Predictive role of Early Interim FDG-PET in Hodgkin Lymphoma.

A Phase II Trial of R-FM (Rituximab, Fludarabine and Mitoxantrone) Chemotherapy Followed by Yttrium 90 ( 90 Y) Ibritumomab Tiuxetan ( 90 Y-IT) for Untreated Follicular Lymphoma (FL) Patients.

A Phase II Trial of Rituximab-CHOP Chemotherapy Followed by Yttrium 90 ( 90 Y) Ibritumomab Tiuxetan ( 90 Y-IT) for Previously Untreated Elderly Diffuse Large B-Cell Lymphoma (DLBCL) Patients.

ITF2357, a Novel Histone-Deacetylase Inhibitor, Is Effective against Peripheral T-Cell Lymphomas in Vivo

FDG-PET in the Serial Assessment of Patients with Lymphoma in Complete Remission.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only